FY2028 Earnings Forecast for PolyPid Issued By HC Wainwright

PolyPid Ltd. (NASDAQ:PYPD) – Investment analysts at HC Wainwright raised their FY2028 earnings per share (EPS) estimates for shares of PolyPid in a research note issued to investors on Wednesday, February 11th. HC Wainwright analyst B. Folkes now expects that the company will post earnings per share of $0.21 for the year, up from their prior estimate of $0.20. HC Wainwright currently has a “Buy” rating and a $13.00 price target on the stock. The consensus estimate for PolyPid’s current full-year earnings is ($1.79) per share. HC Wainwright also issued estimates for PolyPid’s FY2030 earnings at $4.02 EPS.

PolyPid (NASDAQ:PYPD) last announced its quarterly earnings results on Wednesday, February 11th. The company reported ($0.41) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.34) by ($0.07).

A number of other research firms have also recently commented on PYPD. Wall Street Zen upgraded PolyPid from a “sell” rating to a “hold” rating in a research note on Sunday, November 16th. Citigroup reiterated a “market outperform” rating on shares of PolyPid in a report on Monday, December 1st. Weiss Ratings restated a “sell (d-)” rating on shares of PolyPid in a report on Monday, December 29th. Finally, Roth Mkm cut their price target on shares of PolyPid from $10.00 to $9.00 and set a “buy” rating on the stock in a research note on Thursday, November 13th. Five equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to MarketBeat, PolyPid has a consensus rating of “Moderate Buy” and a consensus price target of $12.25.

PolyPid Stock Performance

NASDAQ:PYPD opened at $4.62 on Thursday. PolyPid has a fifty-two week low of $2.30 and a fifty-two week high of $5.12. The company has a 50 day moving average price of $4.35 and a 200 day moving average price of $3.80. The stock has a market capitalization of $73.44 million, a P/E ratio of -1.55 and a beta of 1.52.

Institutional Investors Weigh In On PolyPid

A number of hedge funds have recently bought and sold shares of the stock. BNP Paribas Financial Markets grew its position in shares of PolyPid by 56.1% during the third quarter. BNP Paribas Financial Markets now owns 9,734 shares of the company’s stock worth $32,000 after buying an additional 3,500 shares in the last quarter. HighTower Advisors LLC purchased a new stake in shares of PolyPid during the fourth quarter worth approximately $44,000. Lumbard & Kellner LLC acquired a new stake in PolyPid in the second quarter valued at approximately $135,000. Finally, AIGH Capital Management LLC lifted its stake in PolyPid by 27.0% in the second quarter. AIGH Capital Management LLC now owns 1,194,108 shares of the company’s stock worth $4,215,000 after acquiring an additional 253,727 shares during the last quarter. Institutional investors and hedge funds own 26.47% of the company’s stock.

Key PolyPid News

Here are the key news stories impacting PolyPid this week:

• Positive Sentiment: HC Wainwright reaffirmed a “Buy” and published aggressive long-range forecasts (FY2030 EPS $4.02) and a $13 price target, implying substantial upside versus current levels. This institutional bullish view supports investor optimism about long-term value. Article Title
• Positive Sentiment: Corporate update: PolyPid says it is in advanced-stage U.S. commercial partnership discussions for its D-PLEX100 product — a potential near‑term commercial catalyst that could materially change revenue prospects if a deal is signed. Article Title
• Positive Sentiment: Earnings call highlighted an actionable 2026 catalyst (management tone described as upbeat), which supports the positive analyst outlook if milestones are met. Article Title
• Neutral Sentiment: HC Wainwright modestly increased its FY2028 EPS view to $0.21 (from $0.20) — a small modeling tweak that supports the analyst’s longer-term thesis but is not a near-term revenue confirmation.
• Negative Sentiment: Q4 EPS missed expectations: PolyPid reported ($0.41) vs. consensus ($0.34), underscoring current profitability challenges and contributing to downward pressure on the stock. Article Title
• Negative Sentiment: Short interest rose ~44.8% in January (to ~27.9k shares), a signal of growing bearish positioning; although absolute short percentage is small (~0.2% of float), the increase can amplify near-term downside on negative news.

About PolyPid

PolyPid Ltd is a clinical‐stage biotechnology company focused on polymer‐based drug delivery technologies designed to enhance the performance of therapeutic agents at mucosal surfaces. Leveraging its proprietary Mucoadhesive & Mucus‐Penetrating (MMP) platform, PolyPid develops long‐acting formulations for ocular, oral and pulmonary indications. Its lead candidates include OncoTears and OralTear, therapies targeting dry eye and dry mouth conditions, respectively, as well as Paclical, a polymer‐formulated paclitaxel designed to improve tolerability and antitumor activity in oncology patients.

Founded in 2003 and headquartered in Jerusalem, Israel, PolyPid has assembled an international patent portfolio covering key markets in North America, Europe and Asia.